Department of Ophthalmology, Aarhus University Hospital, Aarhus, Denmark.
Acta Ophthalmol. 2018 Nov;96(7):744-748. doi: 10.1111/aos.13773. Epub 2018 Apr 24.
Diabetic maculopathy can be treated with intravitreal injection of vascular endothelial growth factor (VEGF) inhibitors. However, the therapy is not effective in all patients, and it would be desirable to have parameters for differentiating patients who will benefit from treatment from those who will not. Retinal fixation has been shown to be impaired in patients with low visual acuity (VA) secondary to macular disease, but the changes in fixational eye movements after anti-VEGF treatment for diabetic maculopathy have not been investigated.
Retinal fixation was studied in 29 patients with diabetic macular oedema before three monthly anti-VEGF injections, and 1 and 4 months after the last injection. The change in VA was correlated with changes in area, frequency, amplitude and total number of fixational saccades.
During three monthly injections, best-corrected visual acuity (BCVA) increased from (mean ± SD) 74.0 ± 11.5 Early Treatment Diabetic Retinopathy Study (ETDRS) letters to 78.3 ± 9.8 ETDRS letters, (p = 0.003) and central retinal thickness (CRT) decreased from (mean ± SD) 441.7 ± 107.0 μm to 339.5 ± 74.2 μm, (p = <0.0001), which was followed by the opposite changes after treatment (BCVA reduced nonsignificantly to 77.5 ± 10.4 ETDRS letters (p = 0.06), and CRT increased to 393.0 ± 9.8 μm, p = <0.0001). Both improvement and worsening of BCVA correlated with the fixation area (r = 0.28, p = 0.003 and r = 0.14, p = 0.045, respectively), but only improvement of BCVA correlated with the frequency (r = 0.15, p = 0.037) and total number of saccades (r = 0.18, p = 0.02). BCVA showed no correlation with the amplitude and most frequently occurring saccade amplitude.
Fixational eye movements may be used to monitor short-term effects of anti-VEGF treatment on diabetic macular oedema. Future studies should aim at investigating a possible predictive value of fixational eye movements for visual function in the long term.
玻璃体内注射血管内皮生长因子(VEGF)抑制剂可治疗糖尿病性黄斑病变。然而,并非所有患者均对此治疗有效,因此若能找到相关参数来区分治疗有效和无效的患者将是十分理想的。已有研究表明,继发于黄斑病变的低视力(VA)患者的视网膜固视功能受损,但针对糖尿病性黄斑病变接受抗 VEGF 治疗后的固视眼运动变化情况尚未得到研究。
本研究纳入 29 例糖尿病性黄斑水肿患者,分别在三次每月抗 VEGF 注射前、末次注射后 1 个月和 4 个月时对视网膜固视进行检测。VA 的变化与固视性眼跳的面积、频率、幅度和总数的变化相关。
在三次每月的注射过程中,最佳矫正视力(BCVA)从(均值±标准差)74.0±11.5 个早期治疗糖尿病性视网膜病变研究(ETDRS)字母增加至 78.3±9.8 ETDRS 字母(p=0.003),中央视网膜厚度(CRT)从(均值±标准差)441.7±107.0μm 降低至 339.5±74.2μm(p<0.0001),治疗后则出现相反的变化(BCVA 无显著降低至 77.5±10.4 ETDRS 字母(p=0.06),CRT 增加至 393.0±9.8μm,p<0.0001)。BCVA 的改善和恶化均与固视面积相关(r=0.28,p=0.003 和 r=0.14,p=0.045),但仅 BCVA 的改善与频率(r=0.15,p=0.037)和总的眼跳数量(r=0.18,p=0.02)相关。BCVA 与幅度和最常发生的眼跳幅度均无相关性。
固视眼运动可用于监测抗 VEGF 治疗对糖尿病性黄斑水肿的短期疗效。未来的研究应致力于调查固视眼运动对长期视力的可能预测价值。